Intervention Protocol

High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data

  1. Holger Schulz1,*,
  2. Corinne Brillant1,
  3. Guido Schwarzer2,
  4. Sven Trelle3,
  5. Alexander Greb4,
  6. Julia Bohlius5,
  7. Andreas Engert1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD007580


How to Cite

Schulz H, Brillant C, Schwarzer G, Trelle S, Greb A, Bohlius J, Engert A. High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007580. DOI: 10.1002/14651858.CD007580.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    German Cochrane Center, Department of Medical Biometry and Statistics, Freiburg, Germany

  3. 3

    University of Bern, Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, Bern, Switzerland

  4. 4

    Cologne, Germany

  5. 5

    University of Bern, Division of International & Environmental Health, Institute of Social and Preventive Medicine, Bern, Switzerland

*Holger Schulz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. hschulz@pioh.de.

Publication History

  1. Publication Status: New
  2. Published Online: 21 JAN 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the effectiveness of high-dose chemotherapy regimens plus autologous stem cell transplantation, with or without rituximab, for treating aggressive non-Hodgkin's lymphoma, and in specific subgroups of patients (prognostic groups) in comparison with a standard CHOP-like regimen, with or without rituximab.